Michael Walach, the President of Quest Vision Care Specialty Lab and the CEO of QLDS, a cloud-based digital lens design global provider, holder of several US and international utility patents in the field of ophthalmic lenses and lens technology, has been granted a new, Broadview Natural Addition Lens (NAL®) efficacy patent number U.S. 11,126,012.
The new free-form multifocal NAL® is unique in that it gives single vision-like viewing experience with the performance of a multifocal lens and does not require the Fitting Height value.
“The time has come that after more than half a century and hundreds of design patents and free-form technology advancements based on the PAL utility patent of Bernard Maitenaz a fresh multifocal lens concept is here” said Walach. “The OMNILUX® lens was developed utilizing the NAL® eye-lens ergonomic model is a significant improvement over PAL mainly that the adaptation period is not required, no Fitting Height measurement when dispensing or ordering. In the lab it is edged and inspected just like a single vision lens which improves production efficiency, reduces costly redos, and increases patient viewing comfort”.
QLDS software uses the VCA Lens Design Communication protocol for communicating with Laboratory Management Systems (LMS). QLDS is the exclusive provider of the NAL® technology, licensing digital free-form labs worldwide. For more information visit the QLDS website at qlds.eu.